Analysis of chromatin accessibility associated with azacitidine response in higher-risk myelodysplastic neoplasms.

ABSTRACT: Azacitidine, used in the treatment of higher-risk myelodysplastic neoplasms, is a DNA methyltransferase inhibitor that modifies epigenetic regulatory programs. The efficacy of azacitidine varies among patients, with approximately 50% of patients failing to respond. However, whether epigenomic factors affect responses to azacitidine has not been investigated. We examined chromatin accessibility in bone marrow cells from 23 treatment-naive patients with higher-risk myelodysplastic syndrome, suggesting azacitidine response is strongly associated with distinct hematopoietic cell states. Chromatin-accessible regions in non-responders were enriched for myeloid progenitor signatures, whereas those in responders were enriched for T cell signatures. Notably, CD8⁺ T cells from non-respond

SUBMITTER: Kim D 

PROVIDER: S-EPMC12396253 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature